Guelph, ON
Guelph, ON – November 9, 2021, Zentek Ltd. (“ZEN” or the
“Company”) (TSX-V:ZEN and OTC:ZENYF), a Canadian IP development
and commercialization company focused on next-gen healthcare
solutions, is pleased to provide an update on its leading-edge rapid
detection platform:
• ZEN has contracted NeoVentures Biotechnology Inc. – a world
leader in aptamer development and applications – which has
validated the McMaster results against spike proteins and
is currently optimizing and simplifying the technology in
preparation for regulatory submission and commercial production.
NeoVentures and ZEN are also working to develop a model to
further improve detection limits and sensitivity
• ZEN has contracted axiVEND – specialists in the development
and production of biosensors – to optimize the automated
process of producing sensors on which customized aptamers will
be deposited
• Through consultation with potential partners and in tandem with
McMaster, developed an improved aptamer with a higher binding
affinity for the COVID-19 Delta variant.
• Reduced the three-buffer methodology developed by the
McMaster team to a two-buffer approach to simplify the user
experience which would more easily support widespread adoption
• Optimized the production time of the aptamer-based sensor from
18 hours to 30 minutes with more consistent results
• Formalizing a research collaboration with McMaster to develop
and produce new aptamers for high-priority, communicable
pathogens on a recurring basis
• In active discussions with partners for key aspects of the supply
chain and detection platform, including consumables, hardware,
software and data management
“In collaboration with our partners, including Dr. Li and his entire
McMaster team, we have made tremendous
progress advancing our aptamer-based rapid detection
platform toward commercialization. A key aspect of the technology is
its adaptability through the production of new aptamers to detect
different pathogens leveraging the existing platform –
and the process of building out this aptamer and diseasedetection library is well underway with our colleagues at McMaster.
We believe our combination of accuracy, speed, ease of use, scalability
and affordability is unique in the market, and we will continue working
diligently with our partners to optimize the technology
and commercialize it as efficiently and effectively as possible,”
commented Greg Fenton, Zentek CEO.
About Zentek Ltd.
Zentek is a nanotechnology company developing and commercializing
next-gen healthcare solutions in the areas of prevention, detection and
treatment. Zentek is currently focused on commercializing ZENGuardTM,
a patent-pending coating with 99% antimicrobial activity, including
against COVID-19, and the potential to use similar compounds as
pharmaceutical products against infectious diseases. The company also
has an exclusive agreement to be the global commercializing partner
for a newly developed, highly scalable, aptamer-based rapid pathogen
detection technology.
For further information:
Email: investorrelations@zentek.com
To find out more about Zentek Ltd., please visit our website
at www.zentek.com.
A copy of this news release and all material
documents in respect of the Company may be obtained on ZEN’s SEDAR profile
at www.sedar.ca.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward looking statements address future events and conditions, by their very
nature they involve inherent risks and uncertainties.
Although Zentek believes that the assumptions and factors used in preparing
the forward-looking information in this news release are reasonable, undue
reliance should not be placed on such information, which only applies as of
the date of this news release, and no assurance can be given that such
events will occur in the disclosed time frames or at all. Zentek disclaims any
intention or obligation to update or revise any forward-looking information,
whether as a result of new information, future events or otherwise, other
than as required by law. Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
About Zentek Ltd.
Zentek is a graphene technology company focused on the research, development, and commercialization of graphene-based novel products to give our commercial partners a competitive advantage by making their products better, safer and greener.
Zentek's patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
Our second technology platform is ZenARMOR™, which is patent-pending and focused on corrosion protection applications
To find out more about Zentek Ltd., please visit our website at www.zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR profile at www.sedar.com.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.